Polar Asset Management Partners’s Psyence Biomedical Warrant PBMWW Stock Holding History

Polar Asset Management Partners’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6K	Hold	733,000	–	–	﹤0.01%	803
2026 Q1	$13.3K	Hold	733,000	–	–	﹤0.01%	646
2025 Q4	$13.6K	Hold	733,000	–	–	﹤0.01%	638
2025 Q3	$18.5K	Hold	733,000	–	–	﹤0.01%	617
2025 Q2	$14.9K	Hold	733,000	–	–	﹤0.01%	556
2025 Q1	$12.4K	Hold	733,000	–	–	﹤0.01%	485
2024 Q4	$10.6K	Hold	733,000	–	–	﹤0.01%	617
2024 Q3	$9.24K	Hold	733,000	–	–	﹤0.01%	654
2024 Q2	$7.7K	Hold	733,000	–	–	﹤0.01%	646
2024 Q1	$51.3K	Buy	+733,000	New	+$45.7K	﹤0.01%	580

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Polar Asset Management Partners's PBMWW Position: Q2 2026 in Review

Polar Asset Management Partners held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 733,000 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

Polar Asset Management Partners first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $51.3K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Polar Asset Management Partners held 733,000 shares of Psyence Biomedical Warrant worth $16.6K as of Q2 2026.
Polar Asset Management Partners left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Polar Asset Management Partners's portfolio in Q2 2026, its #803 holding.
Polar Asset Management Partners first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Polar Asset Management Partners's Psyence Biomedical Warrant position peaked at $51.3K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Polar Asset Management Partners's 13F filing for Q2 2026, filed 14 Aug 2026.